Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2011-05-10
2011-05-10
Parkin, Jeffrey S. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S188100, C424S199100
Reexamination Certificate
active
07939083
ABSTRACT:
This invention provides a modified gp140 envelope polypeptide of an HIV-1 isolate comprising a gp120 polypeptide portion comprising consecutive amino acids and a gp41 ectodomain polypeptide portion comprising consecutive amino acids, said gp41 ectodomain polypeptide portion being modified to comprise isoleucine (I) at an amino acid position equivalent to amino acid position 535; glutamine (Q) at an amino acid position equivalent to amino acid position 543; serine (S) at an amino acid position equivalent to amino acid position 553; lysine (K) at an amino acid position equivalent to amino acid position 567; and arginine (R) at an amino acid position equivalent to amino acid position 588, the amino acid positions being numbered by reference to the HIV-1 isolate KNH1144. This invention also provides nucleic acids encoding such a polypeptide, vectors, host cells, trimeric complexes and compositions thereof. Also provided are antibodies generated against the modified polypeptides and trimeric complexes, and methods of using the modified polypeptides, compositions and trimeric complexes.
REFERENCES:
patent: 5474914 (1995-12-01), Spaete
patent: 5886163 (1999-03-01), Hasel et al.
patent: 5935579 (1999-08-01), Habeshaw et al.
patent: 6171596 (2001-01-01), Warl et al.
patent: 6602705 (2003-08-01), Barnett et al.
patent: 6710173 (2004-03-01), Binley et al.
patent: 6911205 (2005-06-01), Sodroski et al.
patent: 7022324 (2006-04-01), Binley et al.
patent: 7105655 (2006-09-01), Sodroski et al.
patent: 7479553 (2009-01-01), Binley et al.
patent: 2004/0191269 (2004-09-01), Lu et al.
patent: 2004/0224308 (2004-11-01), Binley et al.
patent: 2004/0259075 (2004-12-01), Dimitrov et al.
patent: 2005/0089526 (2005-04-01), Moore et al.
patent: 2006/0051373 (2006-03-01), Olson et al.
patent: 2006/0094049 (2006-05-01), Binley et al.
patent: WO 01/00648 (2001-01-01), None
patent: WO 03/022869 (2003-03-01), None
patent: WO 03/087757 (2003-10-01), None
patent: WO 2004/087201 (2004-10-01), None
patent: WO 2006/002079 (2006-01-01), None
patent: WO 2006/002079 (2006-01-01), None
Gerhardt, M., et al., 2005, In-depth, longitudinal analysis of viral quasispecies from an individual triply infected with late-stage human immunodeficiency virus type 1, using a multiple PCR primer approach, J. Virol. 79(13):8249-8261.
Charpentier, C., et al., 2006, Extensive recombination among human immunodeficiency virus type 1 quasispecies makes an important contribution to viral diversity in individual patients, J. Virol. 80(5):2472-2482.
Holland, J. J., et al., 1992, RNA virus populations as quasispecies, Curr. Topics Microbiol. Immunol. 176:1-20.
Beddows, S., et al., 2006, Construction and characterization of soluble, cleaved, and stabilized trimeric Env proteins based on HIV type 1 Env subtype A, AIDS Res. Human Retrovir. 22(6):569-79.
Dowling, W. E., et al., 2002, Forty-one near full-length HIV-1 sequences from Kenya reveal an epidemic of subtype A and A-containing recombinants, AIDS 16:1809-1820.
International Search Report issued by the International Searching Authority (ISA/US) on Sep. 15, 2008 in connection with International Application No. PCT/US2007/022227.
Written Opinion of the International Searching Authority issued by the International Searching Authority (ISA/US) on Sep. 15, 2008 in connection with International Application No. PCT/US2007/022227.
U.S. Appl. No. 09/340,992, filed Jun. 25, 1999, Binley et al.
U.S. Appl. No. 10/117,366, filed Apr. 5, 2002, Binley et al.
U.S. Appl. No. 60/141,168, filed Jun. 25, 1999, Binley et al.
U.S. Appl. No. 60/370,410, filed Apr. 5, 2002, Binley et al.
U.S. Appl. No. 60/317,775, filed Sep. 6, 2001, Moore et al.
U.S. Appl. No. 60/370,264, filed Apr. 5, 2000, Moore et al.
U.S. Appl. No. 60/317,910, filed Sep. 6, 2001, Moore et al.
U.S. Appl. No. 60/317,909, filed Sep. 6, 2001, Binley et al.
U.S. Appl. No. 60/317,764, filed Sep. 6, 2001, Binley et al.
U.S. Appl. No. 60/580,229, filed Mar. 5, 2004, Schülke and Olson.
Atwell, et al. (1997) “Stable Heterodimers From Remodeling the Domain Interface of a Homodimer Using a Phage Display Library” J. Mol. Biol. 270:26-35.
Barouch, D.H. et al. (2002) “Eventual AIDS Vaccine Failure in the Rhesus Monkey by Viral Escape From Cytotoxic T Lymphocytes” Nature 415:335-339.
Barouch, D.H. et al. (2000) “DNA Vaccination for HIV-1 and SIV” Intervirol. 4:282-287.
Binley, J.M. et al. (2002) “Enhancing the Proteolytic Maturation of Human Immunodeficiency Virus Type 1 Envelope Glycoproteins.” J. of Virology, 76 (6): 2606-2616.
Binley, J.M. et al. (2000) “A Recombinant Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Complex Stabilized by an Intermolecular Disulfide Bond Between the gp120 and gp41 Subunits Is an Antigenic Mimic of the Trimeric Viron-Associated Structure” J. Virol. 627-643.
Burton, D.R. et al. (1994) “Efficient Neutralization of Primary Isolates of HIV-1 by a Recombinant Human Monoclonal Antibody” Science 266:1024-1027.
Burton, D.R. et al. (1998) Why Do We Not Have an HIV Vaccine and How Can We Make One? Nature Med. Vaccine Suppl. 4(5):495-498.
Cao, J. et al. (1993) “Effects of Amino Acid Changes in the Extracellular Domain of the Human Immunodeficiency Virus Type 1 Gp41 Envelope Glycoprotein” J. Virol. 67(5):2747-2755.
Cao, et al. (1997) “Replication and Neutralization of Human Immunodeficiency Virus Type 1 Lacking the V1 and V2 Variable Loops of the gp120 Envelope Glycoprotein” J. Virol. 71:9808-9812.
Chen, S. (1993) “Mutational Analysis of the Leucine Zipper-Like Motif of the Human Immunodeficiency Virus Type 1 Envelope Transmembrane Glycoprotein.” J. of Virology 67 (6):3615-3619.
Creson, J. (1999) “The Mode and Duration of Anti-CD28 Costimulation Determine Resistance to Infection by Macrophage-Tropic Strains of Human Immunodeficiency Virus Type 1 In Vitro.” J. of Virology 73(11):9337-9347.
Ditzel H J et al. (1997) “Mapping the Protein Surface of Human Immunodeficiency Virus Type 1 gp 120 Using Human Monoclonal Antibodies From Phage Display Libraries” J. of Molecular Biology, 267 (3):684-695.
Edinger, et al. (1999) “Functional Dissection of CCR5 Coreceptor Function Through the Use of CD4-Independent Simian Immunodeficiency Virus Strains” J. Virol. 73:4062-4073.
Farzan, M. et al. (1998) “Stabilization of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Trimers by Disulfide Bonds Introduced Into the gp 41 Glycoprotein Ectodomain” J. Virol. 72:7620-7625.
Fouts, et al. (1998) “Interactions of Polyclonal and Monoclonal Anti-Glycoprotein 120 Antibodies With Oligomeric Glycoprotein 120-Glycoprotein 41 Complexes of a Primary HIV Type 1 Isolate: Relationship to Neutralization” AIDS Res Human Retrovir. 14:591-597.
Fouts, et al. (1997) “Neutralization of the Human Immunodeficiency Virus Type 1 Primary Isolate JR-FL by Human Monoclonal Antibodies Correlates With Antibody Binding to the Oligomeric Form of the Envelope Glycoprotein Complex” J. Virol. 71:2779-2785.
Gallaher, et al. (1995) “A General Model for the Surface Glycoproteins of HIV and Other Retroviruses” AIDS Res. Human Retrovir. 11:191-202.
Haynes, B.F. (1996) “Update on the Issues of HIV Vaccine Development” Ann. Med. 28:39-41.
Haynes, B.F. (1996) “HIV Vaccines: Where Are We and We Are We Going?” Lancet 348:933-937.
Helseth, E. et al. (1991) “Human Immunodeficiency Virus Type 1 gp120 Envelope Glycoprotein Regions Important for Association With the gp41 Transmembrane Glycoprotein” J. Virol. 65(4):2119-2123.
Ishikawa et al. (1998) “Rapid Formation of the Immune Complexes on Solid Phase in the Immune Complex Transfer Enzyme Immunoassays for HIV-1 P24 Antigen and Antibody IiFfs to HIV-1” J. of Virol. 12:227-237.
Johnston, M.I. et al. (2001) “Progress in HIV Vaccine Develoment” Curr. Op. Pharmacol. 1(5):504-510.
Josephson, et al. (1999) “High-Efficiancy Intracellurlar Magne
Dey Antu K.
Franti Michael
Iyer Sai Prasad N.
Kang Yun (Kenneth)
Moore John P.
Cooper & Dunham LLP
Parkin Jeffrey S.
Progenics Pharmaceuticals Inc.
White John P.
LandOfFree
Soluble, stabilized, proteolytically cleaved, trimeric HIV-1... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Soluble, stabilized, proteolytically cleaved, trimeric HIV-1..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Soluble, stabilized, proteolytically cleaved, trimeric HIV-1... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2655527